The Madrid-based medtech company Thytech has raised €350,000 to advance its cell therapy aimed at preventing transplant rejection.

BStartup Health, the Banco Sabadell program dedicated to financing early-stage healthcare companies, has led the €350,000 funding round for Thytech, a company specialized in cell therapy. The round also included participation from Genesis Biomed and other private investors.

The company, founded by researchers from the Hospital General Universitario Gregorio Marañón, has developed a therapy with multiple applications capable of preventing transplant rejection as well as autoimmune processes. Preliminary results have been positive in preventing heart transplant rejection in infants, in a therapy that “opens the door to reducing the use of immunosuppressive drugs” in such procedures.

According to Rafael Correa Rocha, director of the Immuno-Regulation Laboratory at Gregorio Marañón Hospital, Thytech’s strategy could “open a new era in the treatment of many conditions associated with harmful inflammatory processes,” including the most severe cases of COVID-19.

Albert Figueras, Deputy General Manager of Banco Sabadell, highlighted the technological and medical potential of the initiative, expressing hope that the investment will help bring the therapy “to market and to patients.”

More info: viaempresa.cat